Increase of immunity to rubella and interruption of rubella transmission in Gipuzkoa (Basque Country, Spain) after an enhaced vaccination programme

Epidemiology and Infection

Volumn 132, Issue 4, 2004, Pages 685-692

  Cilla, G ^a   Dorronsoro, M ^b   Saenz Dominquez J R ^c   Serrano, E ^a   Perez Trallero E ^a,c  

^a HOSPITAL DONOSTIA   (Spain)

^b Subdirección de Salud Pública y Adicciones de Guipúzkoa   (Spain)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; RUBELLA ANTIBODY; RUBELLA VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILD HEALTH CARE; CHILDBIRTH; CONGENITAL RUBELLA SYNDROME; CONTROLLED STUDY; DISEASE TRANSMISSION; ERADICATION THERAPY; FEMALE; GEOGRAPHY; HEALTH CARE POLICY; HEALTH PROGRAM; HOSPITAL CARE; HUMAN; IMMUNITY; INFECTION SENSITIVITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RUBELLA; SPAIN; VACCINATION; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; PREGNANCY; PRESCHOOL CHILD;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREGNANCY; PREVALENCE; RUBELLA; RUBELLA VACCINE; SPAIN; VACCINATION;

EID: 4143112634     PISSN: 09502688     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0950268804002158     Document Type: Article

References (29)

1. Chantler J, Wolinsky JS, Tingle A. Rubella virus. In: Knipe DM, Howley P, Griffin DE, Lamb RA, Martin MA, Roizman B, Straus SE, eds. Fields virology, vol. 1, 4th edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 963-990.
2. World Health Organization. Rubella vaccines. WHO position paper. Wkly Epidemiol Rec 2000; 75: 161-172.
3. Cutts FT, Robertson SE, Diaz-Ortega JL, Samuel R. Control of rubella and congenital rubella syndrome (CRS) in developing countries, part 1: burden of disease from CRS. Bull World Health Organ 1997; 75: 55-68.
4. Reef SE, Frey TK, Theall K, et al. The changing epidemiology of rubella in the 1990s. On the verge of elimination and new challenges for control and prevention. JAMA 2002; 287: 464-472.
5. Tookey PA, Peckham CS. Surveillance of congenital rubella in Great Britain, 1971-1996. BMJ 1999; 318: 769-770.
6. Spika JS, Wassilak S, Pebody R, et al. Measles and rubella in the World Health Organization European Region: diversity creates challenges. J Infect Dis 2003; 187 (Suppl 1): S191-S197.
7. Dirección General de Salud Pública. Ministerio de Sanidad y Seguridad Social. Vigilancia Epidemiológica de la Rubéola (II) [Epidemiological surveillance of rubella (II)]. Bol Epidemiol Semanal 1980: semana 25 (no. 1438): 193-195.
8. Salleras L. Estrategias actuales de la prevención de la rubéola congénita [Current strategies in the prevention of congenital rubella]. Med Clin (Barcelona) 1989; 92: 378-381.
9. Pérez-Trallero E, Cilla G, Dorronsoro M, Sáenz-Dominguez JR. Rubella in Guipúzcoa (Basque Country, Spain). A four year serosurvey. Eur J Epidemiol 1991; 7: 183-187.
10. Parkman PD. Making vaccination policy: the experience with rubella. Clin Infect Dis 1999; 28 (Suppl 2): S140-S146.
11. Plotkin SA, Katz M, Cordero JF. The eradication of rubella. JAMA 1999; 281: 561-562.
12. Peltola H, Davidkin I, Paunio M, Valle M, Leinikki P, Heinonen OP. Mumps and rubella eliminated from Finland. JAMA 2000; 284: 2643-2647.
13. Böttiger M, Forsgren M. Twenty years' experience of rubella vaccination in Sweden: 10 years of selective vaccination (of 12-year-old girls and of women post-partum) and 13 years of a general two-dose vaccination. Vaccine 1997; 15: 1538-1544.
14. Pebody RG, Edmunds WJ, Conyn-van Spaendonck M, et al. The seroepidemiology of rubella in western Europe. Epidemiol Infect 2000; 125: 347-357.
15. Gabutti G, Rota MC, Salmaso S, et al. Epidemiology of measles, mumps and rubella in Italy. Epidemiol Infect 2002; 129: 543-550.
16. Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319: 1462-1466.
17. Dykewicz CA, Kruszon-Moran D, McQuillan GM, et al. Rubella seropositivity in the United States 1988-1994. Clin Infect Dis 2001; 33: 1279-1286.
18. Bath SK, Singleton JA, Strikas RA, Stevenson JM, McDonald LL, Williams WW. Performance of US hospitals on recommended screening and immunization practices for pregnant and postpartum women. Am J Infect Control 2000; 28: 327-332.
19. Muñoz-González F, Sánchez-Muñoz C, González-Sánchez M, Sanchez-Laínez J, Ló pez-de Castro F, Rufino G. La inmunidad frente a la rubéola en embarazadas en el área de salud de Toledo [Immunity to rubella in pregnant women in the health area of Toledo]. Aten Primaria 1996; 17: 596-597.
20. Henquell C, Bournazeau JA. Vanlieferinghen P, et al. Recrudescence en 1997 des infections rubéoliques pendant la grossesse. 11 cas á Clermont-Ferrand [The re-emergence in 1997 of rubella infections during pregnancy. 11 cases in Clermont-Ferrand]. Presse Med 1999; 28: 777-780.
21. Miller E, Waight P, Gay N, et al. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep CDR Rev 1997; 7: R26-R32.
22. Pérez-Trallero E, Cilla G, Urbieta M. Rubella immunisation of men: advantages of herd immunity. Lancet 1996; 348: 413.
23. Amela C, Pachón I, de Ory F. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a seroepidemiological survey. Eur J Epidemiol 2003; 18: 71-79.
24. Vidal J, Salleras L, Dominguez A, Plans P. Prevalencia de inmunidad frente a la rubéola en Cataluña [Prevalence of rubella immunity in Catalonia (Spain)]. Vacunas Invest Pract 2001; 2: 86-90.
25. Martinez-Campillo F, Maura da Fonseca A, Santiago J, et al. Estudio de la cobertura vacunal e intervención con agentes de salud comunitarios en población infantil marginal gitana de Alicante [Vaccine coverage study and intervention with health community agents in a marginal gypsy community of Alicante]. Aten Primaria 2003; 15: 234-238.
26. Klevens RM, Luman ET. US children living in and near poverty: risk of vaccine-preventable diseases. Am J Prevent Med 2001; 20 (Suppl): S41-S46.
27. Guala A, Paoletti R, Pastore G, Sinaccio C, Pagani L. Offering rubella vaccination to sexually active adolescents. Vaccine 2003; 21: 1561.
28. Echevarría C, Echevarría JM, Anda P, et al. Infecciones congénitas y perinatales por agentes víricos, Toxoplasma gondii y Treponema pallidum [Congenital and perinatal infections caused by viral agents Toxoplasma gondii and Treponema pallidum. Study of 2000 cases and analysis of 488 positive cases]. Estudio de 2000 casos y análisis de 488 casos positivos. Med Clín (Barcelona) 1987; 88: 129-134.
29. Amela C, Pachón I, Álvarez E, Sanz C. Sarampión, rubéola y parotiditis: situación actual [Measles, rubella and mumps: current situation]. Bol Epidemiol Semanal 2000; 8: 229-232.